Hemosol Announces Webcast of Fourth Quarter and Year-End Conference Call

Apr 03, 2001, 01:00 ET from Hemosol Inc.

    TORONTO, April 3 /PRNewswire/ - Hemosol Inc. (NASDAQ:   HMSL, TSE: HML)
 today announced that its financial results for the three-month and year ended
 December 31, 2000 will be released following the close of the U.S. financial
 markets on April 5, 2001. The Company will hold a conference call to discuss
 these results at 4:30p.m. Eastern time on April 5, 2001.
     A live audio webcast of the conference call will be available through
 www.investorlook.com. Please connect to this website at least 15 minutes prior
 to the conference call to ensure adequate time for any software download that
 may be needed to hear the webcast. A replay of the webcast will be available
 for 30 days starting on April 6, at www.investorlook.com and www.hemosol.com.
 A replay of the conference call will also be available by telephone from
 approximately 6:00p.m. Eastern time on April 5 through April 9, 2001. To
 access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter reservation
 number 737859.
     Minimum requirements to listen to the live broadcast are: a computer with
 speakers, the RealPlayer software, downloadable free from
 www.real.com/products/player/index.html, and an active connection to the
 Internet. If you experience problems listening to the broadcast, go to
 www.financialdisclosure.ca and click the 'test' tab.
 
     About Hemosol Inc.
     Hemosol is an integrated biopharmaceutical company focused on the
 development of a portfolio of products for the treatment of hemoglobin
 deficiencies. Hemosol has a broad range of products in development which
 include: hemoglobin-based oxygen carriers, including Hemolink(TM); hemoglobin
 therapeutics to treat a variety of diseases such as hepatitis C, cancers of
 the liver; and cell therapy for possible therapeutic use to treat cancer, HIV-
 infection and auto-immune diseases. Hemolink(TM), Hemosol's flagship product,
 is a highly purified human-derived hemoglobin replacement product that is
 designed to provide immediate and safe oxygen delivery to vital organs and
 tissues. Potential benefits of Hemolink(TM) include significantly reduced risk
 of transmission of infectious diseases and adverse immune reactions,
 elimination of blood type mismatch and an extended storage life for up to one
 year compared with 42 days for donor blood. Hemosol is also developing methods
 to harvest hemoglobin from cells grown and expanded under controlled
 manufacturing conditions outside the human body.
 
 

SOURCE Hemosol Inc.
    TORONTO, April 3 /PRNewswire/ - Hemosol Inc. (NASDAQ:   HMSL, TSE: HML)
 today announced that its financial results for the three-month and year ended
 December 31, 2000 will be released following the close of the U.S. financial
 markets on April 5, 2001. The Company will hold a conference call to discuss
 these results at 4:30p.m. Eastern time on April 5, 2001.
     A live audio webcast of the conference call will be available through
 www.investorlook.com. Please connect to this website at least 15 minutes prior
 to the conference call to ensure adequate time for any software download that
 may be needed to hear the webcast. A replay of the webcast will be available
 for 30 days starting on April 6, at www.investorlook.com and www.hemosol.com.
 A replay of the conference call will also be available by telephone from
 approximately 6:00p.m. Eastern time on April 5 through April 9, 2001. To
 access the replay, dial, 416-695-5800 or 1-800-408-3053 and enter reservation
 number 737859.
     Minimum requirements to listen to the live broadcast are: a computer with
 speakers, the RealPlayer software, downloadable free from
 www.real.com/products/player/index.html, and an active connection to the
 Internet. If you experience problems listening to the broadcast, go to
 www.financialdisclosure.ca and click the 'test' tab.
 
     About Hemosol Inc.
     Hemosol is an integrated biopharmaceutical company focused on the
 development of a portfolio of products for the treatment of hemoglobin
 deficiencies. Hemosol has a broad range of products in development which
 include: hemoglobin-based oxygen carriers, including Hemolink(TM); hemoglobin
 therapeutics to treat a variety of diseases such as hepatitis C, cancers of
 the liver; and cell therapy for possible therapeutic use to treat cancer, HIV-
 infection and auto-immune diseases. Hemolink(TM), Hemosol's flagship product,
 is a highly purified human-derived hemoglobin replacement product that is
 designed to provide immediate and safe oxygen delivery to vital organs and
 tissues. Potential benefits of Hemolink(TM) include significantly reduced risk
 of transmission of infectious diseases and adverse immune reactions,
 elimination of blood type mismatch and an extended storage life for up to one
 year compared with 42 days for donor blood. Hemosol is also developing methods
 to harvest hemoglobin from cells grown and expanded under controlled
 manufacturing conditions outside the human body.
 
 SOURCE Hemosol Inc.